{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:15:39Z","timestamp":1768212939231,"version":"3.49.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The disease burden associated with COVID-19 continues to significantly impact adults in the United States (US), particularly those aged \u226565 years. While policy discussions often center on the acute phase of severe COVID-19, post-acute outcomes\u2014such as hospital readmissions, post-discharge mortality, and long COVID\u2014likely contribute substantially to the overall burden. This study aimed to estimate the potential impact of hypothetical Fall 2024\/25 single-dose vaccination with Moderna's next-generation mRNA-1283 vaccine on post-acute disease burden in US persons aged \u226512 years, compared with currently available mRNA vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dynamic transmission model was adapted to predict COVID-19 incidence, hospitalizations, and post-acute outcomes for the 2024\/25 season. The model was calibrated using US data, including age-specific COVID-19 hospitalization and vaccination coverage rates from the 2023\/24 season. Post-acute outcomes evaluated included hospital readmissions, post-discharge mortality, and cases of long COVID. Relative vaccine effectiveness of mRNA-1283 compared with current mRNA COVID-19 vaccines mRNA-1273 and BNT162b2 (against infection and hospitalization) was derived from a pivotal Phase 3 trial and an indirect treatment comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to mRNA-1273 and BNT162b2, mRNA-1283 was estimated to prevent in the overall US population an additional 3,132 (vs. mRNA-1273) and 4,517 (vs. BNT162b2) hospital readmissions; 2,604 and 3,757 post-discharge deaths; and 18,450 and 32,382 cases of long COVID, respectively. Approximately 78-79% of readmissions and post-discharge deaths, and 41-42% of long COVID cases were averted among older adults \u226565 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that hypothetical Fall 2024\/25 mRNA-1283 vaccination could substantially reduce post-acute COVID-19 outcomes, particularly among adults aged \u226565 years. By more effectively preventing acute disease, mRNA-1283 may significantly lower post-acute COVID-19 outcomes compared to current mRNA vaccines. The results underscore the importance of considering post-acute disease burden in vaccination policy and support the potential value of next-generation COVID-19 vaccines like mRNA-1283 in optimizing comprehensive COVID-19 prevention in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Disclosures<\/jats:title>\n                    <jats:p>Keya Joshi, PhD, Moderna, Inc.: Employee|Moderna, Inc.: Stocks\/Bonds (Public Company) Michele Kohli, PhD, Moderna, Inc: Advisor\/Consultant|Quadrant Health Economics Inc: Ownership Interest|Quadrant Health Economics Inc: Stocks\/Bonds (Private Company) Michael Maschio, MSc, Moderna, Inc: Advisor\/Consultant Amy Lee, MSc, PhD, Moderna, Inc: Advisor\/Consultant Nicolas Van de Velde, PhD, Moderna, Inc: Stocks\/Bonds (Public Company) Ekkehard Beck, PhD, Moderna, Inc: Employee of Moderna, Inc|Moderna, Inc: Stocks\/Bonds (Public Company)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf695.1797","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:13:48Z","timestamp":1768202028000},"source":"Crossref","is-referenced-by-count":0,"title":["P-1620. Potential Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine on Post-acute Outcomes of COVID-19"],"prefix":"10.1093","volume":"13","author":[{"given":"Keya","family":"Joshi","sequence":"first","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Kohli","sequence":"additional","affiliation":[{"name":"Quadrant Health Economics Inc , Cambridge, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maschio","sequence":"additional","affiliation":[{"name":"Quadrant Health Economics Inc , Cambridge, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Lee","sequence":"additional","affiliation":[{"name":"Quadrant Health Economics , Cambridge, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas Van","family":"de Velde","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,11]]},"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/Supplement_1\/ofaf695.1797\/66352958\/ofaf695.1797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/Supplement_1\/ofaf695.1797\/66352958\/ofaf695.1797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:13:48Z","timestamp":1768202028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf695.1797\/8421622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":0,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2026,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf695.1797","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"ofaf695.1797"}}